
The FINEARTS-HF trial demonstrated that finerenone reduced the risk of worsening heart failure events and cardiovascular death in patients with heart failure and left ventricular ejection fraction ≥40%, regardless of concomitant sodium-glucose co-transporter-2 inhibitor (SGLT2i) use. Among 6,001 participants, 13.6% were treated with an SGLT2i at baseline. Finerenone showed similar benefits in both groups, with rate ratios of 0.83 (95% CI: 0.60 to 1.16) for SGLT2i users and 0.85 (95% CI: 0.74 to 0.98) for non-users (Pinteraction=0.76). During the trial, fewer participants initiated SGLT2i in the finerenone group compared to placebo (17.7% vs. 20.1%). Time-updated analyses confirmed that SGLT2i use did not alter finerenone’s effects. These results suggest that finerenone provides cardiovascular protection independent of SGLT2i use, and combined therapy may offer enhanced benefits.
Like
Save
Share